Akebia Therapeutics (AKBA) Free Cash Flow (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Free Cash Flow of -$22.0 million for Q1 2026, down 61.38% year-over-year from -$56.9 million in Q1 2025, and down 176.43% quarter-over-quarter from $28.7 million in Q4 2025.
Akebia Therapeutics (AKBA) Free Cash Flow (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Free Cash Flow for 14 consecutive years, with -$22.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 61.38% year-over-year to -$22.0 million; the TTM figure through Mar 2026 stood at $57.0 million (up 269.71% YoY), while the FY2025 annual figure was $65.4 million, up 263.27% from the prior year.
- Free Cash Flow slipped to -$22.0 million in Q1 2026 per AKBA's latest filing, from $28.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $28.7 million in Q4 2025 and bottomed at -$54.7 million in Q4 2022.
- Historically, Free Cash Flow has averaged -$5.5 million across 5 years, with a median of -$9.0 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow plunged 239.75% — and 2025, when it surged 853.42%.
- Akebia Therapeutics' Free Cash Flow stood at -$54.7 million in 2022, then soared by 110.73% to $5.9 million in 2023, then plunged by 164.99% to -$3.8 million in 2024, then soared by 853.42% to $28.7 million in 2025, then plunged by 176.43% to -$22.0 million in 2026.
- Business Quant data shows AKBA's Free Cash Flow at -$22.0 million in Q1 2026, $28.7 million in Q4 2025, and $28.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 3.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.13 Mn |
| Jun 30, 2026 | 3.13 Mn |
| Mar 31, 2026 | -21.96 Mn |
| Mar 31, 2026 | -21.96 Mn |
| Dec 31, 2025 | 28.73 Mn |
| Dec 31, 2025 | 28.73 Mn |
| Sep 30, 2025 | 28.03 Mn |
| Sep 30, 2025 | 28.03 Mn |
| Jun 30, 2025 | 22.22 Mn |
| Jun 30, 2025 | 22.22 Mn |
| Mar 31, 2025 | -13.61 Mn |
| Mar 31, 2025 | -13.61 Mn |
| Dec 31, 2024 | -3.81 Mn |
| Dec 31, 2024 | -3.81 Mn |
| Sep 30, 2024 | -7.18 Mn |
| Sep 30, 2024 | -7.18 Mn |
| Jun 30, 2024 | -9.00 Mn |
| Jun 30, 2024 | -9.00 Mn |
| Mar 31, 2024 | -20.05 Mn |
| Mar 31, 2024 | -20.05 Mn |